Pet Drug Reports

Species › Cat

Breed · Cat

Burmese: adverse event reports

FDA breed label "Burmese" · single-breed animals only

194reports, 1989–20260.1% of cat reports
9reports, 12 months to March 202615 in the 12 months before
36.5%classed serious, as reportedall cats: 35.6%
13.4%name selamectinall cats: 14.8%

FDA's database holds 194 reports where the animal's breed is given as "Burmese", shown here as Burmese: 0.1% of reports about cats. Reports on crossbred animals are left out of breed pages.

9 reports arrived in the 12 months to March 2026, down 40% from 15 in the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.

By active ingredient, the drugs named most often are selamectin, spinosad and cefovecin sodium. Selamectin is named in 13.4% of this breed's reports, about the same share as in reports about all cats (14.8%).

The terms listed most often are vomiting (13.9%), anorexia (11.9%) and lethargy (10.3%). Vomiting appears in 13.9% of reports, about the same share as in all cat reports (12.5%). 36.5% of reports stating seriousness were classed as serious, against 35.6% for cats overall.

Drugs named most often, by active ingredient

Active ingredients recorded for the drugReportsShare of Burmese reportsShare of all cat reports
Selamectin2613.4%14.8%
Spinosad199.8%7.8%
Cefovecin sodium189.3%5.8%
Buprenorphine84.1%3.7%
Frunevetmab84.1%5.1%
Propofol84.1%0.8%
Cyclosporine73.6%2%
Fluralaner73.6%7%
Imidacloprid + Moxidectin73.6%5.5%
Butorphanol Tartrate63.1%1.5%
Insulin63.1%2.4%
Isoflurane63.1%1.3%
Nitenpyram63.1%5.8%
Sarolaner + Selamectin63.1%5.3%
Ketamine Hydrochloride52.6%2.5%
Maropitant52.6%2.5%
Amoxicillin42.1%1.1%
Atipamezole Hydrochloride42.1%0.7%
Praziquantel + Pyrantel Pamoate42.1%0.8%
Tiletamine Hydrochloride + Zolazepam Hydrochloride42.1%1.1%

Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.

Signs listed in reports

share of Burmese reports listing the termall cat reports

  1. Vomiting13.9%27
  2. Anorexia[not eating]11.9%23
  3. Lethargy[unusually tired or inactive]10.3%20
  4. Ataxia[unsteady, uncoordinated movement]7.2%14
  5. Depression[dull, quiet or withdrawn]6.2%12
  6. Application site alopecia[hair loss where the product was applied]5.7%11
  7. Behavioural disorder NOS[behaviour change, type not specified]5.7%11
  8. Death5.7%11
  9. Death by euthanasia[the animal was euthanized]5.7%11
  10. Diarrhoea[diarrhea]5.2%10
  11. Emesis[vomiting]4.6%9
  12. Hiding3.6%7
  13. Vocalisation[crying out or unusual noise]3.6%7
  14. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]3.1%6
  15. Fever3.1%6
  16. Hypersalivation[drooling]3.1%6
  17. Apnoea[breathing stopped]2.6%5
  18. Convulsion[seizure]2.6%5
  19. Hypoglycaemia[low blood sugar]2.6%5
  20. Lack of efficacy - NOS[the product did not have the expected effect]2.6%5

Age and weight

Age of the animal

Under 1 year10.8%21
1 to 3 years10.8%21
4 to 7 years23.2%45
8 to 11 years17.5%34
12 years and over35.1%68
Age not given2.6%5

Weight of the animal

Under 5 kg (11 lb)71.1%138
5 to 9.9 kg (11–22 lb)21.1%41
10 to 24.9 kg (22–55 lb)0%0
25 to 44.9 kg (55–99 lb)0%0
45 kg and over (99 lb+)0%0
Weight not given7.7%15

Coloured bar: Burmese reports. Grey bar: all cat reports.

Trend and outcomes

024Apr 2021: 0May 2021: 1Jun 2021: 0Jul 2021: 1Aug 2021: 2Sep 2021: 0Oct 2021: 0Nov 2021: 0Dec 2021: 1Jan 2022: 02022Feb 2022: 0Mar 2022: 0Apr 2022: 0May 2022: 0Jun 2022: 1Jul 2022: 0Aug 2022: 0Sep 2022: 2Oct 2022: 0Nov 2022: 0Dec 2022: 0Jan 2023: 02023Feb 2023: 0Mar 2023: 0Apr 2023: 2May 2023: 0Jun 2023: 1Jul 2023: 1Aug 2023: 1Sep 2023: 1Oct 2023: 2Nov 2023: 0Dec 2023: 0Jan 2024: 22024Feb 2024: 0Mar 2024: 1Apr 2024: 0May 2024: 1Jun 2024: 0Jul 2024: 1Aug 2024: 1Sep 2024: 3Oct 2024: 2Nov 2024: 2Dec 2024: 4Jan 2025: 02025Feb 2025: 0Mar 2025: 1Apr 2025: 2May 2025: 0Jun 2025: 1Jul 2025: 0Aug 2025: 2Sep 2025: 1Oct 2025: 0Nov 2025: 0Dec 2025: 1Jan 2026: 02026Feb 2026: 2Mar 2026: 0

Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcome recorded in the report

Recovered/Normal26.8%52
Recovered with Sequela1%2
Ongoing14.9%29
Died8.2%16
Euthanized3.1%6
Outcome Unknown14.9%29

Beside all cats

MeasureBurmeseAll cats
Reports194148,080
Latest 12 months912,477
Classed serious, of reports stating it36.5%35.6%
Death or euthanasia recorded, per 1,000 reports113.495

Questions about Burmese reports

How many FDA adverse event reports involve Burmeses?

194 reports through March 2026, 0.1% of reports about cats; 9 in the latest 12 months.

Which drugs are named most often in Burmese reports?

By active ingredient: selamectin (26), spinosad (19), cefovecin sodium (18), buprenorphine (8) and frunevetmab (8). Brands are masked in the public data.

What signs are reported most for this breed?

vomiting (13.9%), anorexia (11.9%), lethargy (10.3%), ataxia (7.2%) and depression (6.2%).

Is the Burmese more sensitive to certain drugs?

Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Burmese animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.

Why are crossbreds not included?

FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Breed names are FDA's labels rearranged into everyday order ("Burmese" becomes "Burmese"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.